Your browser doesn't support javascript.
loading
Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas.
Georgiou, Konstantinos; Chen, Longyun; Berglund, Mattias; Ren, Weicheng; de Miranda, Noel F C C; Lisboa, Susana; Fangazio, Marco; Zhu, Shida; Hou, Yong; Wu, Kui; Fang, Wenfeng; Wang, Xianhuo; Meng, Bin; Zhang, Li; Zeng, Yixin; Bhagat, Govind; Nordenskjöld, Magnus; Sundström, Christer; Enblad, Gunilla; Dalla-Favera, Riccardo; Zhang, Huilai; Teixeira, Manuel R; Pasqualucci, Laura; Peng, Roujun; Pan-Hammarström, Qiang.
Afiliación
  • Georgiou K; Clinical Immunology, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital, Huddinge, Sweden;
  • Chen L; Clinical Immunology, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital, Huddinge, Sweden; BGI-Shenzhen, Shenzhen, China;
  • Berglund M; Department of Biosciences and Nutrition, Karolinska Institutet, Solna, Sweden;
  • Ren W; Clinical Immunology, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital, Huddinge, Sweden;
  • de Miranda NF; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands;
  • Lisboa S; Department of Genetics, Portuguese Oncology Institute, and Abel Salazar Biomedical Sciences Institute, Porto University, Porto, Portugal;
  • Fangazio M; Institute for Cancer Genetics, Columbia University, New York, NY;
  • Zhu S; BGI-Shenzhen, Shenzhen, China;
  • Hou Y; BGI-Shenzhen, Shenzhen, China;
  • Wu K; BGI-Shenzhen, Shenzhen, China;
  • Fang W; State Key Laboratory of Oncology in South China and Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China;
  • Wang X; Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China;
  • Meng B; Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China;
  • Zhang L; State Key Laboratory of Oncology in South China and Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China;
  • Zeng Y; State Key Laboratory of Oncology in South China and Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China;
  • Bhagat G; Department of Pathology and Cell Biology, Columbia University, New York, NY;
  • Nordenskjöld M; Department of Molecular Medicine and Surgery, Karolinska Institutet and Karolinska University Hospital, Solna, Sweden; and.
  • Sundström C; Department of Immunology, Genetics and Pathology, Rudbecklaboratoriet, Uppsala University, Uppsala, Sweden.
  • Enblad G; Department of Immunology, Genetics and Pathology, Rudbecklaboratoriet, Uppsala University, Uppsala, Sweden.
  • Dalla-Favera R; Institute for Cancer Genetics, Columbia University, New York, NY;
  • Zhang H; Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China;
  • Teixeira MR; Department of Genetics, Portuguese Oncology Institute, and Abel Salazar Biomedical Sciences Institute, Porto University, Porto, Portugal;
  • Pasqualucci L; Institute for Cancer Genetics, Columbia University, New York, NY;
  • Peng R; State Key Laboratory of Oncology in South China and Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China;
  • Pan-Hammarström Q; Clinical Immunology, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital, Huddinge, Sweden;
Blood ; 127(24): 3026-34, 2016 06 16.
Article en En | MEDLINE | ID: mdl-27030389
ABSTRACT
Diffuse large B-cell lymphoma (DLBCL) is one of the most common and aggressive types of B-cell lymphoma. Deregulation of proto-oncogene expression after a translocation, most notably to the immunoglobulin heavy-chain locus (IGH), is one of the hallmarks of DLBCL. Using whole-genome sequencing analysis, we have identified the PD-L1/PD-L2 locus as a recurrent translocation partner for IGH in DLBCL. PIM1 and TP63 were also identified as novel translocation partners for PD-L1/PD-L2 Fluorescence in situ hybridization was furthermore used to rapidly screen an expanded DLBCL cohort. Collectively, a subset of samples was found to be affected by gains (12%), amplifications (3%), and translocations (4%) of the PD-L1/PD-L2 locus. RNA sequencing data coupled with immunohistochemistry revealed that these cytogenetic alterations correlated with increased expression of PD-L1 but not of PD-L2 Moreover, cytogenetic alterations affecting the PD-L1/PD-L2 locus were more frequently observed in the non-germinal center B cell-like (non-GCB) subtype of DLBCL. These findings demonstrate the genetic basis of PD-L1 overexpression in DLBCL and suggest that treatments targeting the PD-1-PD-L1/PD-L2 axis might benefit DLBCL patients, especially those belonging to the more aggressive non-GCB subtype.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfoma de Células B Grandes Difuso / Antígeno B7-H1 Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Blood Año: 2016 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfoma de Células B Grandes Difuso / Antígeno B7-H1 Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Blood Año: 2016 Tipo del documento: Article